Long-term survival after chemotherapy for acute myeloid leukemia: The experience of the Southwest Oncology Group

Cancer

Volumn 80, Issue 11 SUPPL., 1997, Pages 2199-2204

  Appelbaum, Frederick R ^a,b   Kopecky, Kenneth J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Acute myeloid leukemia; Bone marrow transplantation; Chemotherapy; Long term survival

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0030665228     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971201)80:11+<2199::aid-cncr6>3.0.co;2-d     Document Type: Review

References (13)

1. Morrison FS, Kopecky KJ, Head DR, Athens JW, Balcerzak SP, Gumbart C, et al. Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia: results of a Southwest Oncology Group study of rubidazone vs. Adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and levamisole maintenance. Leukemia 1992; 6:708-14.
2. Hewlett J, Kopecky KJ, Head D, Eyre HJ, Elias L, Kingsbury L, et al. A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): a Southwest Oncology Group study. Leukemia 1995; 9:562-9.
3. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, et al. A randomized investigation of high-dose versus standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. In press.
4. Bodey GP, Freireich EJ, Gehan E, McCredie KB, Rodriguez V, Gutterman J, et al. Late intensification therapy for acute leukemia in remission: chemotherapy and immunotherapy. JAMA 1976; 235:1021-5.
5. Appelbaum FR, Dahlberg S, Thomas ED, Buckner CD, Cheever MA, Clift RA, et al. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia: a prospective comparison. Ann Intern Med 1984; 101:581-8.
6. Champlin RE, Ho WG, Gale RP, Winston D, Selch M, Mitsuyasu R, et al. Treatment of acute myelogenous leukemia: a prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy. Ann Intern Med 1985; 102: 285-91.
7. Peterson BA, Bloomfield CD. Prolonged maintained remissions of adult acute non-lymphocytic leukemia. Lancet 1977;ii:158-60.
8. Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP. High-dose cytosine arabinoside therapy for refractory leukemia. Blood 1983; 62:361-9.
9. Wolff S, Marion J, Stein R. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute non-lymphocytic leukemia in first remission: a pilot study. Blood 1985; 65: 1407-11.
10. Godwin JE, Kopecky KJ, Head DR, Hynes HE, Balcerzak SP, Appelbaum FR. A double blind placebo controlled trial of G-CSF in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1995; 86: 434a.
11. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group study. Blood. In press.
12. Head, D, Kopecky KJ, Weick J, Files JC, Ryan D, Foucar K, et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 1995; 86:1717-28.
13. Banker DE, Groudine M, Norwood T, Appelbaum FR. Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. Blood. In press.